<p>Ospemifene is contraindicated in women with any of the following conditions:</p>

<ul>
	<li>Undiagnosed abnormal genital bleeding</li>
	<li>Known or suspected estrogen-dependent neoplasia</li>
	<li>Active DVT, pulmonary embolism (PE), or a history of these conditions</li>
	<li>Active arterial thromboembolic disease [for example, stroke and myocardial infarction (MI)], or a history of these conditions</li>
	<li>Hypersensitivity (for example, angioedema, urticaria, rash, pruritus) to Ospemifene or any ingredients</li>
	<li>Ospemifene is contraindicated in women who are or may become pregnant. Ospemifene may cause fetal harm when administered to a pregnant woman. Ospemifene was embryo-fetal lethal with labor difficulties and increased pup deaths in rats at doses below clinical exposures, and embryo-fetal lethal in rabbits at 10 times the clinical exposure based on mg/m 2 . If this drug is used during pregnancy, or if a woman becomes pregnant while taking this drug, she should be apprised of the potential hazard to a fetus.</li>
</ul>